Page last updated: 2024-09-03

fosamprenavir and HIV-Associated Lipodystrophy Syndrome

fosamprenavir has been researched along with HIV-Associated Lipodystrophy Syndrome in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Luque, I; Mallolas, J; Pérez-Elias, MJ; Rodríguez-Alcántara, F; Sánchez-Conde, M; Soriano, V1
Murphy, RL1

Reviews

1 review(s) available for fosamprenavir and HIV-Associated Lipodystrophy Syndrome

ArticleYear
Reviving protease inhibitors: new data and more options.
    Journal of acquired immune deficiency syndromes (1999), 2003, Jun-01, Volume: 33 Suppl 1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Oligopeptides; Organophosphates; Pyridines; Pyrones; Sulfonamides

2003

Trials

1 trial(s) available for fosamprenavir and HIV-Associated Lipodystrophy Syndrome

ArticleYear
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
    Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:1

    Topics: Adult; Carbamates; CD4 Lymphocyte Count; Comorbidity; Drug Therapy, Combination; Female; Fever; Furans; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hypercholesterolemia; Hypertriglyceridemia; Male; Organophosphates; Ritonavir; RNA, Viral; Spain; Sulfonamides; Viral Load; Viremia

2009